Beijing Biocytogen, a CRO that provides gene-modified animal models for biomedical research, closed a $77 million Series D venture funding round. The D round was led by China Life Healthcare Fund and SDIC Venture Capital. Last year, the company raised $65 Million in a C round. Founded in 2008, Biocytogen has branches in Beijing, Haimen /Jiangsu, Shanghai and Boston. Bioocytogen generates custom gene-modified animal models/cell lines, breeds and produces animal models, and provides preclinical testing services for immunoncology molecules and therapeutic antibodies. Source: China Biotoday
